Abstract:Shuai Li, Xue Han, Jing Ma, Guo-Hong Huang, Shu-Ting Yang, Chang-Min Wang Clinical Laboratory Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, 830001, People's Republic of China Correspondence: Chang-Min Wang, Department of Clinical Laboratory Center, People's Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Street, Tianshan District, Urumqi, Xinjiang, 830001, People's Republic of China, Tel +86 13609992616, Fax +86− 9918564168, Email Objective: To investigate the value of metagenomic Next-Generation Sequencing (mNGS) in diagnosing Pneumocystis jirovecii pneumonia (PJP) in non-human immunodeficiency virus (HIV)-infected patients. Methods: In this retrospective study, non-HIV-infected patients with PJP and those diagnosed with non-PJP from August 2022 to December 2024 were selected as subjects. The presence of Pneumocystis jirovecii (PJ) and other co-pathogens in bronchoalveolar lavage fluid (BALF) was analyzed, and the diagnostic efficacy of NGS, polymerase chain reaction (PCR) and serum 1,3-β-D-glucan (BDG) in PJP was compared with the reference standard of clinical compound diagnosis. Results: Eighty-nine non-HIV-infected patients were recruited, with dyspnea as the primary symptom (69.66%) and solid malignant tumor as the most common underlying disease (20.22%). Taking clinical compound diagnosis as the reference standard, the sensitivity, specificity, negative predictive value and positive predictive value of mNGS were higher than those detected by PCR and serum BDG. Among 42 non-HIV-infected patients with PJP who underwent mNGS and conventional pathogen detection of BALF, 6 had simple PJ infection and 36 had combined PJ infection. The detection rate of mNGS in mixed infections was significantly higher than that of conventional pathogen detection (85.71 vs 61.70%, P = 0.012). A total of 127 pathogens were detected in BALF using mNGS, among which fungi had the highest detection rate (46.46%). The fungi, viruses and bacteria detected were mainly Pneumocystis jirovecii , human gammaherpesvirus 4 and Acinetobacter baumannii . Conclusion: mNGS is highly effective in diagnosing non-HIV-infected patients with PJP and exhibits ideal performance in the detection of co-pathogens. In addition, it has certain value for clinical diagnosis and guidance of targeted anti-infective drug treatment. Keywords: metagenomic next-generation sequencing, Pneumocystis jirovecii pneumonia, polymerase chain reaction, non-HIV infection Pneumocystis jirovecii pneumonia (PJP) is an acute or subacute pneumonia resulting from infection with Pneumocystis jirovecii (PJ). It may initially cause dyspnea, fever, and dry cough, and in severe cases, death. 1 As an opportunistic infection, it occurs in immunocompromised or compromised hosts and is one of the most common complications of human immunodeficiency virus (HIV). It also frequently makes inroads on non-HIV immunocompromised people with hematological malignancies, hematopoietic stem cell transplantation, autoimmune diseases, inflammatory diseases, and immunosuppressive therapy. 2 Recent decades have witnessed a decrease in the incidence and mortality of PJP in HIV-infected patients due to routine use of chemoprophylaxis and antiretroviral therapy. 3 In contrast, the incidence of PJP in non-HIV-infected patients increased significantly. 4 Studies have shown that the mortality rate of PJP in HIV-infected patients is less than 10%, while it is as high as 25% to 55% in non-HIV-infected patients. 5 Delayed diagnosis and treatment of PJP will affect the prognosis of patients and bring a huge economic burden to families and society. Therefore, pathogen identification and clinical intervention of PJP should be carried out at an early stage, which is crucial to reduce mortality and improve the prognosis of patients. In the previous practice, the diagnosis of PJP depended on observing respiratory specimens under a microscope after routine or immunofluorescence staining. However, the low fungal load and low sensitivity of routine staining resulted in negative reports that were far from sufficient to rule out a diagnosis of PJP. In addition, immunofluorescence staining is not routinely performed in many hospitals. 6 1,3-β-D-glucan (BDG) is currently a common serological biomarker for auxiliary diagnosis of PJP, but it lacks specificity. 7 Polymerase chain reaction (PCR) is widely used to detect PJ because of its good sensitivity and specificity, but it has limited value in single detection of mixed infection. 8 Therefore, there is an urgent need to explore a more accurate and efficient microbial diagnostic tool for detec -Abstract Truncated-

Identifying optimal serum 1,3-β-D-Glucan cut-off for diagnosing Pneumocystis Jirovecii Pneumonia in non-HIV patients in the intensive care unit

Negative serum (1,3) -β-D-glucan has a low power to exclude Pneumocystis jirovecii pneumonia (PJP) in HIV-uninfected patients with positive qPCR

Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis

-D-Glucan for Differential Diagnosis of Pneumocystis jirovecii Pneumonia and Pneumocystis jirovecii Colonisation</p>

Variable reliability of the (1,3)-β-d-glucan test for screening Pneumocystis pneumonia in HIV-negative patients depending on the underlying condition

Clinical Performance of BAL Metagenomic Next-Generation Sequence and Serum (1,3)-β-D-Glucan for Differential Diagnosis of Pneumocystis jirovecii Pneumonia and Pneumocystis jirovecii Colonisation

Value of 1-3-β-D glucan in diagnosis of AIDS-related Pneumocystis pneumonia

Interpretation of results of PCR and B-D-glucan for the diagnosis of Pneumocystis Jirovecii Pneumonia in immunocompromised adults with acute respiratory failure

Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIV-infected patients: a retrospective case control study

Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

Clinical diagnosis value of serum(1,3)-β-D glucan to invasive pulmonary fungal infection

Study on mNGS Technique in Diagnosing Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Patients

Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumocystis jiroveci Pneumonia in Immunocompromised Patients

The diagnostic value of detecting plasma 1,3-β-D-glucan for invasive fungal infections

Prognostic value of serial (1,3)-β-d-glucan measurements in ICU patients with invasive candidiasis

1701. Differences in Diagnostic Performance of Β-D-glucan Testing in Patients with Varying Degrees of Susceptibility to Invasive Fungal Infections

Diagnostic performance of the (1-3)-β-d-glucan assay in patients with different risks for invasive fungal diseases

[Investigation of the Cutoff Value of a Serum 1,3-Beta-d-glucan Assay for Early Diagnosis of Invasive Fungal Infection in Chinese Hematopoietic Stem Cell Transplant Recipients].

Clinical evaluation of two different (1,3)-ß-d-glucan assays for diagnosis of invasive fungal diseases: A retrospective cohort study

Recent Advances in the Diagnosis of Pneumocystis Pneumonia.

Diagnostic and Preventive Significance of Fungal Detection Combined with (1, 3) Β-D Glucan Detection for Pulmonary Fungal Infection